Related Experiment Videos
Potentially lethal arrhythmias and their management in hypertrophic cardiomyopathy
Insights
Potentially lethal arrhythmias (PLA) incidence in hypertrophic cardiomyopathy patients on beta-blockers is high, with many developing over time. New arrhythmias often occur without symptoms, highlighting the need for vigilant monitoring.
Area of Science:
- Cardiology
- Electrophysiology
- Internal Medicine
Background:
- Potentially lethal arrhythmias (PLA) are a concern in hypertrophic cardiomyopathy (HCM).
- Long-term incidence data for PLA in HCM patients is lacking.
- Beta-adrenergic blocking drugs are commonly used for HCM management.
Purpose of the Study:
- To determine the incidence of new potentially lethal arrhythmias (PLA) in patients with hypertrophic cardiomyopathy (HCM) during long-term follow-up.
- To assess the types of PLA, including conduction system disease (CSD) and ventricular arrhythmias.
- To evaluate the role of symptoms and diagnostic methods in detecting these arrhythmias.
Main Methods:
- Prospective study of 50 HCM patients treated with high-dose beta-blockers.
- Long-term follow-up (2-14 years) using electrocardiograms, 24-hour Holter monitoring, and exercise stress testing.
- Actuarial analysis to calculate the incidence of new PLAs.
Main Results:
- Twenty-one patients (42%) developed 24 new PLAs during follow-up.
- Conduction system disease (CSD) incidence reached 33% at 10 years; ventricular couplets or VT incidence reached 75% at 10 years.
- Only 43% of new PLAs were associated with new symptoms; Holter monitoring detected most ventricular arrhythmias.
Conclusions:
- Potentially lethal arrhythmias (PLA) develop with significant incidence in HCM patients on beta-blockers over time.
- New arrhythmias frequently occur asymptomatically, underscoring the limitations of symptom-based detection.
- Regular Holter monitoring is crucial for identifying ventricular arrhythmias in this patient group.
Abstract:
The prevalence of potentially lethal arrhythmias (PLA) in groups of patients with hypertrophic cardiomyopathy has been assessed, but the rate at which they develop (their incidence) during long-term follow-up has not been reported. Therefore, conduction system disease (CSD) (sick sinus syndrome and His-ventricular disease), ventricular couplets and ventricular tachycardia (VT) detected by routine electrocardiograms, periodic 24-hour Holter monitoring and periodic exercise stress testing were studied in 50 patients treated with large doses of beta-adrenergic blocking drugs who were followed for 2 to 14 years (mean 5.9). Sixteen PLAs detected at the beginning of observation were excluded from actuarial analysis for new PLAs . Twenty-one patients had 24 new PLAs (7 with CSD, 1 patient with sustained supraventricular tachycardia, 6 with ventricular couplets and 10 with VT); only 43% of these PLAs were heralded by new symptoms. In 6 patients, the arrhythmia caused symptoms and was identified by a routine electrocardiogram. The 3 patients with His-ventricular disease presented with syncope and required electrophysiologic confirmation of this diagnosis. In only 1 patient was a PLA (ventricular couplets) detected only by exercise testing. All other ventricular arrhythmias were detected by Holter monitoring. The incidence of CSD in 47 patients free of this condition at entry was 5% at 5 years and 33% at 10 years. The incidence of ventricular couplets or VT in 39 patients free of these at entry was 26% at 5 years and 75% at 10 years, and the incidence of VT only was 18% at 5 years and 40% at 10 years.(ABSTRACT TRUNCATED AT 250 WORDS)